Janssen, Legend’s Carvykti approved in US to treat multiple myeloma
In the CARTITUDE-1 study, 98% of patients with RRMM responded to a one-time treatment with Carvykti, while 78%…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Mar 22
In the CARTITUDE-1 study, 98% of patients with RRMM responded to a one-time treatment with Carvykti, while 78%…
28 Feb 22
Through the acquisition, BBL will obtain rights to Viatris’ biosimilars business assets, which is estimated to generate $1bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Feb 22
In the CLEAR/KEYNOTE-581 trial, Keytruda plus Lenvima significantly reduced the risk of disease progression or death by 61%,…
25 Feb 22
The FDA approval is supported by results from the Phase 3 EMPEROR-Preserved trial in which Jardiance showed a…
25 Feb 22
Covifenz leverages CoVLP technology, comprises recombinant spike (S) glycoprotein, and is co-administered with GSK’s pandemic adjuvant
24 Feb 22
Sanofi and GSK’s vaccine is said to have induced superior immune responses and a favourable safety profile, both…
24 Feb 22
Thermo Fisher will provide dedicated capacity to scale-up the production of Moderna’s Covid-19 vaccine, and other potential mRNA…
23 Feb 22
The company has a commercial footprint in 56 countries worldwide and is planning to expand its presence in…
23 Feb 22
The advanced facility will harbour research efforts in Boston and New York to advance the development of RNA…
22 Feb 22
The expanded FDA approval enables patients with Class II heart failure and elevated levels of natriuretic peptides to…